Earlier this month, the stock received a boost after the company announced it had terminated an agreement with Ascendiant Capital for a $10 million at-the-market share offering.

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

BROOMFIELD, CO - January 30, 2025 (NEWMEDIAWIRE) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that it has agreed to sell 506,803 shares of its common stock at a price per share of $9.25 in a registered direct offering priced at the market. All of the shares of common stock in the offering are being sold by Aclarion. The closing of the offering is expected to take place on or about January 31, 2025, subject to the satisfaction of customary closing conditions.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BROOMFIELD, CO - January 28, 2025 (NEWMEDIAWIRE) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced revised timing and a revised split ratio for its pending reverse stock split of its common stock.

Let's dive into the action on the US markets on Monday. Here are the most active stocks that are driving the market today.

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

In today's session, there are notable price gaps in the US markets on Friday. Take a closer look at the stocks that are gap up and gap down.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BROOMFIELD, CO - January 24, 2025 (NEWMEDIAWIRE) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Wednesday, January 29, 2025, it will complete a 1-for-370 reverse stock split of its common stock.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BROOMFIELD, CO - January 17, 2025 (NEWMEDIAWIRE) - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of an underwritten public offering of 100,000 shares of common stock and 143,900,000 pre-funded warrants with each share of common stock and each pre-funded warrant accompanied by (i) a series A common warrant to purchase one (1) common share at an exercise price of $0.20 per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $0.20 per share. The combined public offering price of each share of common stock together with the accompanying series A and series B common warrants is $0.10, and the combined public offering price of each pre-funded warrant together with the accompanying series A and series B common warrants is $0.09999. In addition, the Company granted to the underwriter a 45 day option to purchase up to an additional 21,000,000 shares of its common stock (or pre-funded warrants), at the public offering price, less underwriting discounts and commissions, and up to an additional 21,000,000 series A common warrants and up to an additional 21,000,000 series B common warrants at a nominal price to cover over-allotment sales. The underwriter exercised its option to purchase 21,000,000 series A common warrants and 21,000,000 series B common warrants. All shares of common stock, pre-funded warrants, series A common warrants and series B common warrant were sold by Aclarion. The closing of the public offering occurred on January 16, 2025.